Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: A randomized clinical trial

JAMA Internal Medicine

Volumn 174, Issue 12, 2014, Pages 1947-1954

  Fiellin, David A ^a   Schottenfeld, Richard S ^a   Cutter, Christopher J ^a   Moore, Brent A ^a   Barry, Declan T ^a   O'Connor, Patrick G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; NALOXONE; NALTREXONE; OPIATE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; PRESCRIPTION DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG URINE LEVEL; DRUG WITHDRAWAL; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OPIATE ADDICTION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PRESCRIPTION OPIOID DEPENDENCE; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SELF REPORT; URINALYSIS; WITHDRAWAL SYNDROME; COMPARATIVE STUDY; DRUG ADMINISTRATION; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRIMARY HEALTH CARE; PROCEDURES; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; URINE;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUGS; PRIMARY HEALTH CARE; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; URINALYSIS;

EID: 84919493133     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.5302     Document Type: Article

References (54)

1. Substance Abuse and Mental Health Services Administration. Results From the 2012 National Survey on Drug Use and Health: Summary of National Findings and Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2012.
2. CDC grand rounds: prescription drug overdoses - a US epidemic. Morb Mortal Wkly Rep. 2012;61(1):10-13.
3. Kirschner N, Ginsburg J, Sulmasy LS; Health and Public Policy Committee of the American College of Physicians. Prescription drug abuse: a policy position paper from the American College of Physicians. Ann Intern Med. 2014;160(3):198. doi:10.7326/M13-2209.
4. Center for Substance Abuse Research. Buprenorphine treatment of opioid dependence. CESAR Fax. 2011;20(34). http://www.cesar.umd.edu/cesar/pubs/BuprenorphineCESARFAX.pdf. Accessed September 4, 2014.
5. Greene P. Outpatient drug utilization trends for buprenorphine years 2002-2009. May 10, 2010. http://buprenorphine.samhsa.gov/bwns/2010-presentations-pdf/09-Greene-508.pdf. Accessed September 4, 2014.
6. Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99 (1-3):345-349.
7. Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283(10):1303-1310.
8. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects ofmethadone in the treatment of opioid dependence. Ann Intern Med. 1993;119(1):23-27.
9. Gowing LR, Farrell M, Bornemann R, Sullivan LE, Ali RL. Brief report: methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med. 2006;21(2):193-195.
10. Ball JC, Ross A. The Effectiveness ofMethadone Maintenance Treatment. New York, NY: Springer-Verlag Inc; 1991.
11. Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addicts' risk of fatal heroin overdose. Subst Use Misuse. 1996;31(2):177-196.
12. Zanis DA, Woody GE. One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend. 1998;52(3):257-260.
13. Nielsen S, Hillhouse M, Thomas C, Hasson A, Ling W. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. J Addict Med. 2013;7(1):33-38.
14. Sullivan LE, Chawarski M, O'Connor PG, Schottenfeld RS, Fiellin DA. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend. 2005;79(1):113-116.
15. Sigmon SC, Dunn KE, Saulsgiver K, et al. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry. 2013; 70(12):1347-1354.
16. Moore BA, Fiellin DA, Barry DT, et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med. 2007; 22(4):527-530.
17. Blondell RD, Smith SJ, Servoss TJ, DeVaul SK, Simons RL. Buprenorphine and methadone: a comparison of patient completion rates during inpatient detoxification. J Addict Dis. 2007;26(2):3-11.
18. Seifert J, Metzner C, Paetzold W, et al. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. Addict Biol. 2005;10(2):157-164.
19. Seifert J, Metzner C, Paetzold W, et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs methadone. Pharmacopsychiatry. 2002;35(5): 159-164.
20. Kissin W, McLeod C, Sonnefeld J, Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006;25(4):91-103.
21. Katz EC, Brown BS, Schwartz RP, O'Grady KE, King SD, Gandhi D. Transitioning opioid-dependent patients from detoxification to long-term treatment: efficacy of intensive role induction. Drug Alcohol Depend. 2011;117(1):24-30.
22. Treatment Episode Data Set (TEDS) Highlights: 2007 National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2009. OAS Series S-45.
23. Barry DT, Irwin KS, Jones ES, et al. Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med. 2009;24(2): 218-225.
24. Walley AY, Alperen JK, Cheng DM, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23(9):1393-1398.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text revision.Washington, DC: American Psychiatric Press; 2000.
26. Wei LJ, Lachin JM. Properties of the urn randomization in clinical trials [published correction appears in Control Clin Trials. 1989;10(1):following 126]. Control Clin Trials. 1988;9(4):345-364.
27. Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365-374.
28. Fiellin DA, Barry DT, Sullivan LE, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med. 2013;126(1):e11-e17. doi:10.1016/j.amjmed.2012.07.005.
29. Irvin JE, Bowers CA, Dunn ME,Wang MC. Efficacy of relapse prevention: ameta-analytic review. J Consult Clin Psychol. 1999;67(4): 563-570.
30. Marlatt GA, Gordon JR. Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors. New York, NY: Guilford Press; 1985.
31. Mercer DE, Woody GE. Individual Drug Counseling. Rockville, MD: National Institute on Drug Abuse, Division of Clinical and Research Services;1999.
32. Sobell LC, Sobell MB, Leo GI, Cancilla A. Reliability of a timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict. 1988;83(4):393-402.
33. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Erlbaum Associates; 1988.
34. Little RC, Milliken GA, Stroup WW, Wolfinger RD. SAS System for Mixed Models. Cary, NC: SAS Publishing; 1996.
35. Hardin JW, Hilbe JM. Generalized Estimating Equations. Boca Raton, FL: Chapman & Hall; 2003.
36. Cannon MJ, Warner L, Taddei JA, Kleinbaum DG. What can go wrong when you assume that correlated data are independent: an illustration from the evaluation of a childhood health intervention in Brazil. Stat Med. 2001;20(9-10):1461-1467.
37. Dahmen G, Ziegler A. Generalized estimating equations in controlled clinical trials: hypotheses testing. Biom J. 2004;46(2):214-232.
38. Horton NJ, Lipsitz SR. Review of software to fit generalized estimating equation regression models. Am Stat. 1999;53(2):160-169.
39. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12): 1238-1246.
40. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-Year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662-668.
41. Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial [published corrections appear in JAMA. 2009;301(8):830, and JAMA. 2013;309(14):1461]. JAMA. 2008;300(17):2003-2011.
42. LingW, Hillhouse M, Ang A, Jenkins J, Fahey J. Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction. 2013; 108(10):1788-1798.
43. Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5): 425-431.
44. Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat. 2009;37 (4):426-430.
45. Johanson CE, Arfken CL, di Menza S, Schuster CR. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend. 2012;120(1-3): 190-195.
46. Clark RE, Baxter JD. Responses of state Medicaid programs to buprenorphine diversion: doing more harm than good? JAMA Intern Med. 2013;173(17):1571-1572.
47. Clark RE, Samnaliev M, Baxter JD, Leung GY. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff (Millwood). 2011;30(8):1425-1433.
48. Horgan CM, Reif S, Hodgkin D, Garnick DW, Merrick EL. Availability of addiction medications in private health plans. J Subst Abuse Treat. 2008; 34(2):147-156.
49. Kennedy J, Dipzinski A, Roll J, Coyne J, Blodgett E. Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA. Drug Alcohol Depend. 2011;114(2-3):201-206.
50. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies: tackling the opioid-overdose epidemic. N Engl J Med. 2014;370 (22):2063-2066.
51. Egan JE, Casadonte P, Gartenmann T, et al. The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. J Gen Intern Med. 2010; 25(9):936-941.
52. Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone D. "Every 'never' I ever said came true": transitions from opioid pills to heroin injecting. Int J Drug Policy. 2014;25(2):257-266.
53. Young AM, Havens JR. Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis. Addiction. 2012;107(3):587-596.
54. Grau LE, Dasgupta N, Harvey AP, et al. Illicit use of opioids: is OxyContin a "gateway drug"? Am J Addict. 2007;16(3):166-173.